Clinical Trials Sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Total 18 results

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Advanced Solid Tumor | Advanced Gastric Carcinoma | Advanced Cholangiocarcinoma | Advanced Lung Cancer

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Oncology | CTLA4 Haploinsufficiency

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

CD20-positive B-cell Non-Hodgkin's Lymphoma

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors

Advanced Breast Cancer | Advanced Solid Tumor | Advanced Gastric Cancer

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumor | Classic Hodgkin Lymphoma

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

IMM40H Phase I Dose Escalation and Expansion

Tumor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
IQVIA RDS

Recruiting

A Study Of IMM47 In Subjects With Advanced Solid Tumors

Oncology

Australia
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Worldwide Clinical Trials

Suspended

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

B-cell Non-Hodgkin's Lymphoma

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shandong Cancer Hospital and Institute

Recruiting

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Squamous Cell Cancer of Head and Neck

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Zhejiang Cancer Hospital; Fudan University

Recruiting

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

China
Ark Biosciences Inc.
Shanghai Ark Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

Hypertrophic Scar

China
Ark Biosciences Inc.
Shanghai Ark Biopharmaceutical Co., Ltd.

Completed

A Study of AK3280 in Chinese Healthy Volunteers

Healthy

China
Ark Biosciences Inc.
Shanghai Ark Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China
Hengenix Biotech Inc
Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ Bio-Tech Co., Ltd

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID 19
Shanghai Henlius Biotech
Hengenix Biotech Inc; Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ...

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID-19

Clinical Trials Sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations